Agios Pharmaceuticals (LTS:0HB0) FFO


LTS:0HB0 Agios Pharmaceuticals Inc LTS:0HB0
49 GF Score
Price $43.23
GF Value $86.37
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0HB0
49GF Score
Agios Pharmaceuticals Inc LTS:0HB0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (LTS:0HB0) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of $43.23 is trading 49.9% below its estimated GF Value™ of $86.37. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0HB0:

  • FFO:
  • GF Value™: $86.37 vs. price of $43.23 (49.9% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the LTS:0HB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
49GF Score

Get the complete analysis for LTS:0HB0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.23
Price
$86.37
GF Value